Literature DB >> 20079930

Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation.

Weiyun Shi1, Ting Wang, Lixin Xie, Suxia Li, Hua Gao, Juncai Liu, Huiping Li.   

Abstract

PURPOSE: To study the risk factors, clinical features, and treatment of recurrent fungal keratitis after corneal transplantation.
DESIGN: Retrospective, interventional case series. PARTICIPANTS: Eight hundred ninety-nine patients (eyes) with fungal keratitis who underwent corneal transplantation at the Shandong Eye Institute between January 2000 and October 2008. Six hundred fourteen patients underwent penetrating keratoplasty (PK) and 285 patients underwent lamellar keratoplasty (LK).
METHODS: All patients failed to respond to topical and systemic antifungal drugs treatment before corneal transplantation. A trephine that was 0.5 mm larger in diameter than the infection area was used during PK or LK. Medical records of each patient were reviewed retrospectively. The species of pathogenetic fungi causing recurrence were analyzed. The clinical features, including recurrence time, position, symptom, and physical signs, were summarized. Based on clinical features, appropriate topical and systemic antifungal treatment was determined for all patients; some patients also received combined subconjunctival or intracameral injection of fluconazole. If there was treatment failure, a conjunctival flap or keratoplasty was performed. MAIN OUTCOME MEASURES: Species of pathogenetic fungi, clinical features, and apparent therapeutic effects.
RESULTS: Fifty-seven patients (6.34%) experienced recurrence after corneal transplantation. There was no difference between PK (6.79%) and LK (5.96%) in recurrence rate (P = 0.883). A higher rate of recurrences was found in those with preoperative hypopyon (10.90%), corneal perforation (12.00%), corneal infection expanding to limbus (20.69%), or lens infection with extracapsular cataract extraction (50%; P<0.05). The 3 main kinds of recurrence were: (1) recurrent infection from recipient bed to graft, and once recurrent infection invaded the graft, the inflammation progressed more rapidly; (2) white mushroom-shaped hypopyon with anterior chamber recurrence; (3) infection in the posterior chamber and vitreous opacity on posterior segment recurrence. Location of recurrence was: recipient bed (70.18%), anterior chamber (7.02%), and posterior segment (22.81%). The overall cure rate was 82.46%, which included drug therapy (28.07%) and surgical treatment (54.39%).
CONCLUSIONS: Hypopyon, corneal perforation, corneal infection expanding to limbus and lens infection are major risk factors for recurrence of fungal keratitis after corneal transplantation. Based on the clinical features of recurrence, appropriate treatment options can help to control the recurrent infection. Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079930     DOI: 10.1016/j.ophtha.2009.10.004

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  27 in total

1.  A presentation of culture-positive corneal donors and the effect on clinical outcomes.

Authors:  Aida Hajjar Sesé; Jens Lindegaard; Hanne Olsen Julian; Klavs Højgaard-Olsen; Niels Frimodt Møller; Steffen Heegaard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-11-30       Impact factor: 3.117

2.  Natamycin in the treatment of fungal keratitis: a systematic review and Meta-analysis.

Authors:  Sheng Qiu; Gui-Qiu Zhao; Jing Lin; Xue Wang; Li-Ting Hu; Zhao-Dong Du; Qian Wang; Cheng-Cheng Zhu
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

3.  Results of therapeutic penetrating keratoplasty for bacterial and fungal keratitis.

Authors:  Yusuf Koçluk; Emine Alyamaç Sukgen
Journal:  Int Ophthalmol       Date:  2016-10-08       Impact factor: 2.031

4.  Therapeutic dilemma in fungal keratitis: administration of steroids for immune rejection early after keratoplasty.

Authors:  Ting Wang; Suxia Li; Hua Gao; Weiyun Shi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-24       Impact factor: 3.117

5.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

6.  Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis: A Pilot Clinical Study.

Authors:  Andrea Naranjo; Alejandro Arboleda; Jaime D Martinez; Heather Durkee; Mariela C Aguilar; Nidhi Relhan; Neda Nikpoor; Anat Galor; Sander R Dubovy; Roger Leblanc; Harry W Flynn; Darlene Miller; Jean-Marie Parel; Guillermo Amescua
Journal:  Am J Ophthalmol       Date:  2019-09-05       Impact factor: 5.258

7.  Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea.

Authors:  Jun-Yi Wang; Dian-Qiang Wang; Xiao-Lin Qi; Jun Cheng; Li-Xin Xie
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

8.  Etiological Analysis of Fungal Keratitis and Rapid Identification of Predominant Fungal Pathogens.

Authors:  Dan He; Jilong Hao; Song Gao; Xue Wan; Wanting Wang; Qiushi Shan; Li Wang
Journal:  Mycopathologia       Date:  2015-10-07       Impact factor: 2.574

9.  Early deep anterior lamellar keratoplasty for fungal keratitis poorly responsive to medical treatment.

Authors:  F Sabatino; E Sarnicola; C Sarnicola; G M Tosi; P Perri; V Sarnicola
Journal:  Eye (Lond)       Date:  2017-12-01       Impact factor: 3.775

10.  Etiology and failure analysis of anterior lamellar keratoplasty.

Authors:  Zhen Wang; Xiao-Jun Tan; Hua-Lei Zhai; Jun Cheng; Yan Gao; Li-Xin Xie
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.